Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)

Market Cap	34.05M -55.6%
Revenue (ttm)	36.76M +14.2%
Net Income	-25.78M
EPS	-0.94
Shares Out	30.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,524
Average Volume	74,423
Open	1.155
Previous Close	1.120
Day's Range	1.150 - 1.275
52-Week Range	0.760 - 3.400
Beta	1.09
RSI	54.62
Earnings Date	Apr 15, 2026

About STO:NEWBRY

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NEWBRY

Financial Performance

In fiscal year 2025, STO:NEWBRY's revenue was 31.57 million, a decrease of -14.27% compared to the previous year's 36.83 million. Losses were -23.88 million, 55.0% more than in 2024.